학술논문

Bevacizumab added to neoadjuvant chemotherapy for breast cancer
Document Type
Clinical report
Source
The New England Journal of Medicine. Jan 26, 2012, Vol. 366 Issue 4, p310, 11 p.
Subject
Dosage and administration
Drug therapy
Usage
Patient outcomes
Bevacizumab -- Dosage and administration
Breast cancer -- Drug therapy
Chemotherapy -- Usage
Chemotherapy -- Patient outcomes
Drug evaluation
Cancer -- Chemotherapy
Cancer -- Usage
Cancer -- Patient outcomes
Drugs -- Product/Service Evaluations
Language
English
ISSN
0028-4793
Abstract
The study aims to evaluate whether the addition of bevacizumab added to neoadjuvant chemotherapy would increase the rates of pathological complete responses in women with breast cancer. The results indicated that the use of such therapy did increase the rate of pathological complete response.